Why 2017 Will Be Great for Biotech, Plus a Sell
With Congress’ approval of a new healthcare overhaul, the entire biotech universe is on the verge of major change. With big things to come in 2017, here’s how we can get in now.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.